Having extracted the BRCA1 and BRCA2 genes from human DNA to isolate them as a research subject, Myriad Genetics feels it is entitled to its patent on the new DNA compound, but petitioners in a Supreme Court case are contesting it on the grounds that a company cannot copyright nature.

A. Having extracted the BRCA1 and BRCA2 genes from human DNA to isolate them as a research subject, Myriad Genetics feels it is entitled to its patent on the new DNA compound

B. Having had extracted the BRCA1 and BRCA2 genes from human DNA to isolate them as research subjects, Myriad Genetics now feels it is entitled to its patent on the new DNA compound

C. Having extracted the BRCA1 and BRCA2 genes from human DNA to isolate it as a research subject, Myriad Genetics now feels it is entitled to its patent on the new DNA compound

D. Having extracted the BRCA1 and BRCA2 genes from human DNA to isolate them as research subjects, Myriad Genetics now feels it is entitled to its patents on the new DNA compounds

E. Having extracted the BRCA1 and BRCA2 genes from human DNA to isolate them as research subjects, Myriad Genetics now feels entitled to its patents on the new DNA compound